Dedicated to changing lives by developing novel RNA therapies for people living with severe genetic rare diseases that currently have no treatment options.
Location: Netherlands, South Holland, Leiden
Employees: 51-200
Phone: +31 88 166 7000
Founded date: 2012
Investors 5
| Date | Name | Website |
| - | Medison Ve... | medisonven... |
| - | Foresite C... | foresiteca... |
| - | Gilde Heal... | gildehealt... |
| 26.05.2025 | Retinal De... | retinaldeg... |
| - | Pontifax V... | pontifax.c... |
Mentions in press and media 13
| Date | Title | Description |
| 11.12.2024 | ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration | LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA ed... |
| 13.03.2024 | ProQR Announces Year End 2023 Operating and Financial Results | - |
| 04.10.2022 | A top Wall Street analyst names 3 tiny biotechs that look like takeout targets — including one that could jump more than 1,000% | The British pharma giant AstraZeneca has quietly been working on gene-editing research over the past few years. AstraZeneca This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Redeem now Seve... |
| 04.11.2021 | ProQR Announces Third Quarter 2021 Operating and Financial Results | Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing platfo... |
| 17.06.2021 | PROQR THERAPEUTICS N.V. ProQR Therapeutics N : Plain-language summary of Retina Leroy BP, et al. paper | This plain-language summary (or PLS) describes a paper on Leber congenital amaurosis 10 that was published in a medical journal called "Retina". Title of the paper: Leber congenital amaurosis due to CEP290 mutations - severe visio... |
| 06.05.2021 | PROQR THERAPEUTICS N.V. ProQR Announces First Quarter 2021 Operating and Financial Results | Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromi... |
| 24.03.2021 | ProQR’s RNA therapy on track to pivotal tests in rare, inherited form of vision loss | Netherlands-based ProQR is developing its experimental therapy, QR-421a, as a treatment for Usher syndrome. The rare disorder is caused by mutations to genes that provide the instructions for proteins key to hearing, vision, and balance. Th... |
| 31.03.2020 | Myovant grabs $40M upfront in regional deal for relugolix; Akero announces NASH success but Covid-19 delays | → Having just filed for the European approval of its uterine fibroids drug relugolix, Myovant has sold the regional rights off to Hungarian biotech Gedeon Richter. Comprising $40 million in upfront, $40 million in regu... |
| 14.12.2018 | Shinichi Tamura reclaims the throne at Sosei; Jeff Abbey exits Argos for Novadip; Frank Czerwiec is the new CMO at Goldfinch | → Jeff Abbey is jumping to the helm of Belgium’s Novadip Biosciences after leading Argos Therapeutics as president and CEO for the past eight years. Having led Novadip’s autologous cell therapy through a Phase I/IIa tria... |
| 13.09.2017 | ProQR spins out CNS assets to form RNA rare disease biotech | ProQR has spun out its CNS assets to form Amylon Therapeutics. The offshoot starts life with seed funding and an RNA-based program targeting a rare genetic disease that causes strokes. Amylon will further develop ProQR’s research into beta ... |
Show more